These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1122 related items for PubMed ID: 16790698

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM.
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [Abstract] [Full Text] [Related]

  • 3. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
    Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz MG, Chung J, FitzGerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, Mayes MD, Connolly MK, Fessler BJ, Rothfield NF, Mubarak K, Molitor J, Tashkin DP, Scleroderma Lung Study Group.
    Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
    [Abstract] [Full Text] [Related]

  • 4. Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.
    Mittoo S, Wigley FM, Wise R, Xiao H, Hummers L.
    Arthritis Rheum; 2007 Dec; 56(12):4195-202. PubMed ID: 18050251
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
    Wanchu A, Suryanaryana BS, Sharma S, Sharma A, Bambery P.
    Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
    [Abstract] [Full Text] [Related]

  • 7. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
    Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM, Sclerodema Lung Study II Investigators.
    Lancet Respir Med; 2016 Sep; 4(9):708-719. PubMed ID: 27469583
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
    Bérezné A, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D, Le Guern V, Kahn JE, Couderc LJ, Constans J, Cohen P, Mahr A, Pagnoux C, Hachulla E, Kahan A, Cabane J, Guillevin L, Mouthon L.
    J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
    [Abstract] [Full Text] [Related]

  • 10. Cyclophosphamide for scleroderma lung disease.
    Martinez FJ, McCune WJ.
    N Engl J Med; 2006 Jun 22; 354(25):2707-9. PubMed ID: 16790705
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.
    Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Clements P, Chung J, Elashoff RM, Suh R, Smith EA, Furst DE, Tashkin DP, Scleroderma Lung Study Research Group.
    Am J Respir Crit Care Med; 2008 Jan 01; 177(1):91-8. PubMed ID: 17901414
    [Abstract] [Full Text] [Related]

  • 13. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H, Holland AE, Westall GP, Goh NS, Glaspole IN.
    Cochrane Database Syst Rev; 2018 Jan 03; 1(1):CD010908. PubMed ID: 29297205
    [Abstract] [Full Text] [Related]

  • 14. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study.
    Khanna D, Yan X, Tashkin DP, Furst DE, Elashoff R, Roth MD, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, Clements PJ, Scleroderma Lung Study Group.
    Arthritis Rheum; 2007 May 03; 56(5):1676-84. PubMed ID: 17469162
    [Abstract] [Full Text] [Related]

  • 15. Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.
    Kowal-Bielecka O, Kowal K, Rojewska J, Bodzenta-Lukaszyk A, Siergiejko Z, Sierakowska M, Sierakowski S.
    Ann Rheum Dis; 2005 Sep 03; 64(9):1343-6. PubMed ID: 16100339
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy of ab initio immunosuppressive therapy and steroid-sparing effect in interstitial lung disease associated with antisynthetase antibody syndrome].
    Franzolini N, Quartuccio L, De Marchi G, De Vita S.
    Reumatismo; 2007 Sep 03; 59(3):202-8. PubMed ID: 17898879
    [Abstract] [Full Text] [Related]

  • 17. The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis.
    Broad K, Pope JE.
    Med Sci Monit; 2010 Sep 03; 16(9):RA187-90. PubMed ID: 20802426
    [Abstract] [Full Text] [Related]

  • 18. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline.
    Plastiras SC, Karadimitrakis SP, Ziakas PD, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzelepis GE.
    Arthritis Rheum; 2006 Aug 15; 55(4):598-602. PubMed ID: 16874782
    [Abstract] [Full Text] [Related]

  • 19. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease.
    Várai G, Earle L, Jimenez SA, Steiner RM, Varga J.
    J Rheumatol; 1998 Jul 15; 25(7):1325-9. PubMed ID: 9676764
    [Abstract] [Full Text] [Related]

  • 20. High-dose acetylcysteine in idiopathic pulmonary fibrosis.
    Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M, IFIGENIA Study Group.
    N Engl J Med; 2005 Nov 24; 353(21):2229-42. PubMed ID: 16306520
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.